Published in final edited form as:

Biochemistry. 2011 May 10; 50(18): 3724–3735. doi:10.1021/bi200073f.

Inhibition of Multidrug Resistance-Linked P-Glycoprotein (ABCB1) Function by 5'-Fluorosulfonylbenzoyl 5'-Adenosine: Evidence for an ATP Analog That Interacts With Both Drug-Substrate- and Nucleotide-Binding Sites†

Shinobu Ohnuma[‡], Eduardo Chufan[‡], Krishnamachary Nandigama[‡], Lisa M. Miller Jenkins[‡], Stewart R. Durell[‡], Ettore Appella[‡], Zuben E. Sauna[§], and Suresh V. Ambudkar^{‡,*}

[‡] Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4256

[§] Laboratory of Hemostasis, Division of Hematology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland 20892

Abstract

5'-fluorosulfonylbenzoyl 5'-adenosine (FSBA) is an ATP analog that covalently modifies several residues in the nucleotide-binding domains (NBDs) of several ATPases, kinases and other proteins. P-glycoprotein (P-gp, ABCB1) is a member of the ATP-binding cassette (ABC) transporter superfamily that utilizes energy from ATP hydrolysis for the efflux of amphipathic anticancer agents from cancer cells. We investigated the interactions of FSBA with P-gp to study the catalytic cycle of ATP hydrolysis. Incubation of P-gp with FSBA inhibited ATP hydrolysis (IC_{50} = 0.21 mM) and the binding of 8-azido[α -³²P]ATP (IC_{50} = 0.68 mM). In addition, ¹⁴C-FSBA crosslinks to P-gp, suggesting that FSBA-mediated inhibition of ATP hydrolysis is irreversible due to covalent modification of P-gp. However, when the NBDs were occupied with a saturating concentration of ATP prior to treatment, FSBA stimulated ATP hydrolysis by P-gp. Furthermore, FSBA inhibited the photocrosslinking of P-gp with [¹²⁵I]-Iodoaryl-azidoprazosin (IAAP; IC_{50} = 0.17 mM). As IAAP is a transport substrate for P-gp, this suggests that FSBA affects not only the NBDs, but also the transport-substrate site in the transmembrane domains. Consistent with these results, FSBA blocked efflux of rhodamine 123 from P-gp-expressing cells. Additionally, mass spectrometric analysis identified FSBA crosslinks to residues within or nearby the NBDs but not in the transmembrane domains and docking of FSBA in a homology model of human P-gp NBDs supports the biochemical studies. Thus, FSBA is an ATP analog that interacts with both the drug-binding and ATP-binding sites of P-gp, but fluorosulfonyl-mediated crosslinking is observed only at the NBDs.

The ATP Binding Cassette (ABC) family of transport proteins constitutes one of the largest gene families¹. The clinical importance of this family is apparent from the fact that of the 48

[†]This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

*To whom correspondence should be addressed: Suresh V. Ambudkar, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4256; Tel: 301-402-4178; Fax: 301-435-8188; ambudkar@helix.nih.gov.

SUPPORTING INFORMATION

These data include the effect of DTT on FSBA-P-gp interactions (Fig. S1), the inhibition of photolabeling of P-gp with 8-azido [α -³²P] ATP by FSBA (Fig. S2), modeling of crosslinking of FSBA to peptide #2 in NBD1 (Fig. S3), and alignment of homology models of NBDs of human P-gp based on HlyB and mouse P-gp structures and docking of FSBA (Fig. S4). This is available free of charge at <http://pubs.acs.org>.

human ABC transporters, 17 are implicated in human diseases.² P-glycoprotein (P-gp), the first human ABC transporter to be discovered,³ plays a significant role in multidrug resistance (MDR). MDR is a phenomenon in which cells show resistance to chemically diverse drugs with multiple mechanisms of action and is one of the mechanisms by which tumors become resistant to chemotherapeutic drugs⁴. Thus, significant effort has been expended over the last two decades to understand the mechanism of P-gp in particular and ABC proteins in general [for reviews see⁵⁻⁸]. P-gp is an energy-dependent molecular pump that utilizes the energy of ATP hydrolysis to move drug-substrates across the cell membrane.⁹ The enzymatic hydrolysis of ATP and the transport of drug-substrates are tightly coupled phenomena that occur in different domains of the protein.¹⁰ The movement of drug-substrates occurs as a consequence of conformational changes in the membrane-spanning transmembrane domains (TMDs); ATP hydrolysis occurs at the intracellular nucleotide-binding domains (NBDs). The development of probes for these two regions of the protein has played a significant role in elucidating the catalytic cycle of P-gp-mediated ATP hydrolysis as well as the mechanism of the transport cycle.

ABC transporters have relatively low affinities (in the micro-molar range) for their drug-substrates as well as for nucleotides.¹¹ These low affinities present technical difficulties that have been enumerated in detail by Senior and colleagues.¹² Photoaffinity reagents that can form covalent bonds with the amino acid side chains have proved extremely useful in probing the substrate- and nucleotide-binding sites.¹³ Over the last few decades there has been a concerted effort to design nucleotide-based affinity labels.¹⁴ The general consensus is that labels that incorporate the reactive group into the 5'-hydroxyl group cause minimal perturbation of the adenosine moiety.¹⁵ The Colman group at the University of Delaware has taken the lead in synthesizing and characterizing such reagents. One of the most successful reagents to emerge from their work has been 5'-fluorosulfonylbenzoyl 5'-adenosine (FSBA).

The sulfonylfluoride group of FSBA that replaces the phosphate groups of ATP is a reactive functional group that can react with several amino acids.¹⁶⁻¹⁸ As the sulfonylfluoride participates in a broad range of reactions, there is a reasonable probability of reaction within any particular active site.¹⁵ The sulfonylfluoride acts as an electrophilic agent that has been shown to form covalent bonds with tyrosine, lysine, histidine, serine, and cysteine.¹⁵ Thus, FSBA has been used to localize the nucleotide-binding sites, characterize the active site and study the catalytic mechanism of numerous enzymes. These include the cAMP-dependent protein kinase II,¹⁹ isocitrate dehydrogenase kinase,²⁰ rabbit muscle pyruvate kinase,²¹ myosin, multifunctional protein CAD²² and the mitochondrial F₁-ATPase.²³ This reagent has proved particularly useful in studying the protein kinase family²⁴ and studies show that FSBA produces a stable, isolable product after reacting with the active sites of the enzymes.²⁵ FSBA-protein interactions have been studied extensively, including the effect of FSBA binding and/or crosslinking on enzyme activity and kinetics,^{26, 27} the use of antibodies and LC-MS to identify the sites of FSBA crosslinking²⁸ and the use of [¹⁴C]-labeled FSBA²⁹. Nonetheless, there have been no studies that exploit FSBA to probe the nucleotide-binding sites of ABC transporters.

In this study we show that FSBA interacts with both the nucleotide- and substrate-binding sites of P-gp. In addition, our data demonstrate that FSBA is crosslinked to P-gp. Significantly, FSBA also reverses P-gp-mediated transport of a fluorescent substrate in intact cells. These results show that, as may be expected based on the interactions of FSBA with numerous other proteins (for review, see ¹⁴), this nucleotide analog interacts with the NBDs of P-gp. In addition, we demonstrate that FSBA interacts with the substrate-binding sites in the TMDs of this transporter. A similar dual effect has also been observed with disulfiram, although the mechanism is significantly different. Disulfiram, which is not an

ATP analog, reacts with the Walker A cysteine residue in each NBD, thus inhibiting ATP hydrolysis, while it also interacts at the substrate-binding sites of P-gp.^{30, 31} However, in Cys-less P-gp, it interacts only at the transport-substrate site in the TMDs. FSBA, as an ATP analog, either competes with ATP for binding at the NBDs (even in Cys-less P-gp) or binds to another site and has an effect on ATP binding at NBDs. It also interacts at the drug-binding sites, while ATP does not. Using mass spectrometric analysis, we were able to demonstrate that FSBA crosslinks residues in NBDs (for example, K411 in NBD1) as well as in the regions near NBDs. We were not able to detect FSBA crosslinked peptides originating from the TMDs, suggesting that interaction between the FSBA and the substrate-binding site in TMDs is reversible. In addition, this FSBA interaction at the TMDs does not require functional ATP sites, as the IAAP labeling in the Y401A/Y1044A double mutant lacking ATP-binding capacity is still inhibited by FSBA.

MATERIALS AND METHODS

Chemicals

[¹²⁵I] Iodoarylazidoprazosin ([¹²⁵I]-IAAP), 2,200 Ci/mmol, and [adenine-8-¹⁴C]-FSBA (57 mCi/mmol) were obtained from Perkin Elmer Life Sciences (Boston, MA). 8-azido-[α -³²P]ATP (15–20 Ci/mmol) and 8-azidoATP were purchased from Affinity Labeling Technologies, Inc. (Lexington, KY). The P-gp-specific monoclonal antibody C-219 was obtained from Fujirebio Diagnostics Inc. (Malvern, PA). All other chemicals were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO).

Cell Lines and Culture Conditions

KB-3-1 and P-gp-overexpressing KB-V1 cells were maintained in DMEM supplemented with 10% FBS, penicillin, streptomycin and the KB-V1 cells were grown in media containing 1 μ g/ml vinblastine.³²

Preparation of Crude Membranes From High-Five Insect Cells Infected With Recombinant Baculovirus Carrying the Wild-Type and Mutant Human *MDR1* Gene. High-Five insect cells (Invitrogen, Carlsbad, CA) were infected with the baculovirus carrying the human *MDR1* cDNA (either wild-type or Y401A/1044A or the cys-less mutant where all seven native cysteine residues are replaced with alanine) with a 6X Histidine tag at the C-terminal end as described previously.³³ Crude membranes were prepared and stored at -70°C as described previously.^{33, 34}

Purification and Reconstitution of P-gp

Human P-gp from crude membranes of High Five insect cells was purified as described previously.^{33, 35} The crude membranes were solubilized with octyl β -D-glucopyranoside (1.25%) in the presence of 20% glycerol and a lipid mixture (0.1%). Solubilized proteins were subjected to metal affinity chromatography (Talon resin, Clontech, Palo Alto, CA) in the presence of 0.95% octyl β -D-glucopyranoside and 0.04% lipid; 80% purified P-gp was eluted with 200 mM imidazole. P-gp in the 200 mM imidazole fraction was then concentrated (Centriprep-50, Amicon, Beverly, MA) to $\sim 0.5 - 1.5$ mg/ml and stored at -70°C . P-gp was identified by immunoblot analysis using the monoclonal antibody C219³³ and quantified by the Amido Black protein estimation method as previously described.³⁶ Purified P-gp was reconstituted into proteoliposomes by dialysis using a lipid:protein ratio of 10:1 as described.³⁷ The purified Pgp in proteoliposomes exhibited 50 μM verapamil-stimulated ATPase activity in the range of 1100 to 1300 nmol of P_i /min/mg of protein as previously described^{35, 38}.

ATPase Assay

Crude membranes (10 µg/protein/100 µl) from High Five cells expressing P-gp were incubated at 37°C for 30 min with varying concentrations of FSBA in the presence and absence of sodium orthovanadate (Vi) (0.3 mM) in ATPase assay buffer (50 mM MOPS-KOH, pH 7.5, 50 mM KCl, 5 mM sodium azide, 1 mM EGTA, 1 mM ouabain, 10 mM MgCl₂). The reaction was initiated by the addition of 5 mM ATP and incubated for 20 min at 37°C. SDS solution (0.1 ml of 5% SDS) was added to terminate the reaction and the amount of inorganic phosphate released was quantified with a colorimetric reaction, as described previously.¹¹

Photocrosslinking of 8-azido-[α-³²P]-ATP to P-gp

Crude membranes of High-Five insect cells (50–100 µg of protein) or purified and reconstituted protein (5–10 µg of protein) were incubated in an ATPase assay buffer (50 mM MES-Tris, pH 6.8, 50 mM KCl, 5 mM sodium azide, 1 mM EGTA, 1 mM ouabain and 10 mM MgCl₂) containing 10 µM [α-³²P]8azidoATP (10 µCi/nmol) in the dark at 4°C for 5 min. The samples were irradiated with a UV lamp assembly (PGC Scientifics, Gaithersburg, MD) fitted with two black light (self-filtering) UV-A long wave F15T8BLB tubes (365 nm) for 10 min on ice (4°C). Ice-cold ATP (10 mM) was added to displace excess non-covalently bound 8azido-[α-³²P]ATP. After SDS-PAGE on a 7% NuPAGE gel, the gels were dried and exposed to Bio-Max MR film (Eastman Kodak Co.) at –70°C for 12–24 h. The radioactivity incorporated into the P-gp band was quantified using the STORM 860 PhosphorImager system (Molecular Dynamics, Sunnyvale, CA) and the software ImageQuaNT. One phase decay mode was used to fit the data given in Figure S2 (additional details are given in the legend to Fig. S2).

Photoaffinity Labeling with [¹²⁵I]IAAP

The crude membranes of High-Five insect cells (60–75 µg protein/100 µl) were incubated at room temperature in ATPase buffer with [¹²⁵I]-IAAP (5–7 nM) for 5 min under subdued light. The samples were photocrosslinked for 5 min at room temperature followed by electrophoresis and quantification as described previously.³⁴ Modifications to this procedure in specific experiments are detailed in the figure legends.

Chemical Crosslinking of P-gp with [¹⁴C]-FSBA

Purified and reconstituted P-gp (15–40 µg protein) was incubated with 100 µM [¹⁴C]-FSBA for 30 min at 37°C. The reaction was stopped by the addition of SDS-PAGE loading buffer and the samples were electrophoresed on a 7% NuPage gel at constant voltage. The dried gel was used to quantify the radioactivity incorporated into the P-gp using the STORM 860 PhosphorImager system with a high sensitivity screen and ImageQuaNT software.

Mass Spectrometry

Protein bands were cut from polyacrylamide gels and the proteins were in-gel alkylated with 55 mM iodoacetamide, for 45 min at 25°C. Following washing with 50 mM ammonium bicarbonate, the proteins were in-gel trypsin digested for 16 h at 25°C using a Montage In-Gel Digest Kit (Millipore, Billerica, MA) on a 96-well C18 ZipPlate following the manufacturer's guidelines. Peptides were eluted from the plate and an aliquot of each digestion reaction was analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) on a MALDI micro MX (Waters, Milford, MA) to look for modified peptides. To determine the sites of modification, the remaining peptides were acidified by 1:1 dilution with Diluent Buffer containing 2% acetonitrile, 0.1% formic acid, and 0.05% HFBA in water. Separation of the peptides was performed at 500 nL/min and was coupled to online analysis by tandem mass spectrometry (nLC-ESI-MS/MS) on an

LTQ ion trap mass spectrometer (ThermoElectron, San Jose, CA) equipped with a nanospray ion source. From the diluted peptides, 30 μ L were loaded onto a 0.1 $\times$ 150 mm Magic C18AQ column (Michrom Bioresources, Inc, Auburn, CA) inline after a nanotrap column using the Paradigm MS4 MDLC (Michrom Bioresources, Inc., Auburn, CA). Elution of the peptides into the mass spectrometer was performed with a linear gradient from 95% mobile phase A (2% acetonitrile, 0.5% acetic acid, 97.5% water) to 65% mobile phase B (10% water, 0.5% acetic acid, 89.5% acetonitrile) in 45 minutes and then to 95% mobile phase B in 5 minutes. The peptides were detected in positive ion mode using a mass list containing the masses of the modified peptides identified by MALDI-TOF MS analysis.

Molecular Modeling

A Nucleotide Binding Domain homology model of human P-gp was constructed using the X-ray crystal structure of the ABC transporter haemolysin-B (Hly-B), in complex with ATP/ Mg^{2+} , as the template (1XEF.pdb).³⁹ Residues K408, P1045, T1046, R1138 and V1139, missing in the Hly-B structure, were included in the final model, importing three loops from the X-ray structure of the ABC transporter associated with antigen processing TAP1 (2IXF.pdb).⁴⁰ The fragments incorporated into the model were the following: PNHPNVQVLQ (residues 27–36 of TAP1-NBD1); PNHPNVQVLQGL (residues 27–38 of TAP1-NBD2) and LTRTPT (residues 117–122 of TAP1-NBD2). Protein residues were *in-silico* mutated to the P-gp sequence, and the side-chain conformations of the new residues were visually inspected and modified when necessary. The structure was energy-minimized by CHARMM.⁴¹ Docking studies of FSBA at the NBDs were carried out using the program Vina-Autodock⁴² or by manually positioning the FSBA molecule with its adenine group π -stacked to the Y401 and adjusting the torsion angles of rotatable bonds. After ligand docking, the protein-FSBA structures were energy-minimized by CHARMM.

Fluorescent Substrate Accumulation Assay by Flow Cytometry

Accumulation assays with rhodamine 123 (0.5 $\mu\text{g}/\text{ml}$) were carried out in P-gp-expressing KB-V-1 cells as described previously.⁴³ For all samples, 10,000 events were counted and analysis was performed with Cell Quest (Becton-Dickinson Immunocytometry systems). The mean fluorescence intensity was calculated using the histogram stat program in Cell Quest software.

RESULTS

FSBA Inhibits Drug Transport in Intact Cells Over-Expressing P-gp

FSBA, which is an analog of ATP, has been used to identify and characterize the nucleotide-binding sites of several ATP dependent proteins,¹⁵ but had not been used in the study of ABC transporters. The structure of FSBA strongly resembles that of ATP, except for the presence of 5'-fluorosulfonyl-benzoyl in place of the phosphoryl groups of ATP (Fig. 1A,B). We used a flow cytometry based assay to investigate the effect of FSBA on P-gp-mediated drug transport. Flow cytometry using fluorescent transport-substrates of P-gp has been extensively used to measure transport function.⁴⁴ Cells over-expressing P-gp accumulate less fluorescent substrate, such as the typically used rhodamine 123 than parental cells not expressing P-gp. Treatment of P-gp-over-expressing cells with modulators that interact with P-gp decreases the efflux of the transport-substrate and increases accumulation of the fluorescent substrates to levels seen in the parental cells.⁴⁴ Fig. 2 clearly shows that KB-V1 cells that over-express P-gp accumulate lower levels of rhodamine 123 than the parental KB-3-1 cells. Treatment of the KB-V1 cells with the P-gp modulator XR9576 increases rhodamine 123 levels comparable to those observed in KB-3-1 cells. When the P-gp-expressing cells were incubated with 1.5 mM FSBA for 45 min at 37°C, the accumulation of rhodamine 123 also increased. The increase in the fluorescence signal was equivalent to that

observed in the presence of XR9576, which is a well characterized inhibitor of P-gp-mediated transport.⁴⁵ To further elucidate the mechanism of FSBA action, we investigated the effect of FSBA on both P-gp-mediated ATP hydrolysis as well as P-gp drug-substrate interactions.

Characterization of FSBA-Mediated Inhibition of the ATPase Activity of P-gp

As the structure of FSBA strongly resembles that of ATP (Fig. 1A,B), we determined its effect on ATP hydrolysis by P-gp. Fig. 3A shows that FSBA inhibits P-gp-mediated ATP hydrolysis in a concentration-dependent manner ($IC_{50} = 0.21 \pm 0.05$ mM mean $\pm$ SD, $n=3$), with the possibility that FSBA has an effect on ATP hydrolysis either by binding directly to the nucleotide-binding domains (NBDs) of P-gp or elsewhere on the molecule. The $t_{1/2}$ for the inhibition of P-gp-mediated ATP hydrolysis by FSBA is 3.75 ± 1.72 min (mean $\pm$ SD, $n=3$), determined by incubating P-gp with FSBA for increasing lengths of time at 37°C, prior to initiating ATP hydrolysis (Fig. 3B). In addition, we observed that FSBA-mediated inhibition of ATP hydrolysis is temperature-dependent (Fig. 3C). The time and temperature dependence suggests that inhibition of ATP binding alone is not sufficient for FSBA-mediated inhibition; chemical crosslinking is also necessary. Studies on rabbit pyruvate kinase have shown that the inhibition of this enzyme by FSBA can be partially reversed by the reducing agent dithiothreitol (DTT).²¹ The experiments described above were carried out in the absence of DTT. We found that the addition of DTT prevents the FSBA-mediated inhibition of ATPase activity with an apparent EC_{50} of 0.07 mM (Supplemental Fig. S1A). Further experiments were carried out to investigate whether DTT could reverse FSBA-mediated inhibition once the covalent crosslink had formed. Treatment with DTT after incubating P-gp with FSBA for 30 min at 37°C shows only a modest reversal of this inhibition (supplemental Fig. S1B: compare III and IV). Thus, if the P-gp is incubated with DTT during FSBA treatment, inhibition of ATPase activity is prevented (Fig S1A); however, once the reaction between FSBA and the amino acid side chains has progressed to completion, it cannot be reversed by DTT (Fig. S1B). Thus, the prevention of the FSBA-inhibitory effect of ATP hydrolysis can be ascribed to a quenching effect of DTT on FSBA, when both are added at the same time to initiate the reaction.

[¹⁴C]FSBA Crosslinks to Purified P-gp

The work described above suggests that FSBA crosslinks to P-gp and this is established more directly with the data presented in Fig. 4. Purified P-gp, reconstituted into proteoliposomes, was incubated with [¹⁴C]-FSBA for 30 min at 37°C. The reaction was stopped by the addition of SDS-PAGE loading buffer and the sample was subjected to gel electrophoresis. In Fig. 4A, which is an autoradiogram, we show that the [¹⁴C] signal is associated with the P-gp band, demonstrating that the [¹⁴C]-FSBA is crosslinked to the P-gp. When the [¹⁴C]-FSBA was incubated with P-gp in the presence of 10 mM ATP, however, there was 50% reduction but not elimination of [¹⁴C]FSBA crosslinking to P-gp. In addition, we observed comparable levels of [¹⁴C]-FSBA crosslinking to wild type P-gp and a cys-less mutant (Fig. 4B), where all seven native cysteine residues have been replaced by alanine. This implies that the cysteine residues are not necessary for the observed crosslinking of FSBA to P-gp.

FSBA Stimulates ATP Hydrolysis if the Nucleotide-Binding Sites Are Occupied by Saturating Concentrations of ATP

If FSBA binds to the NBDs, it should be possible to test its effect when these sites are occupied by ATP at saturating concentration. In the experiment shown in Fig. 5A, the NBDs were occupied with saturating concentration of ATP (5 mM) prior to the addition of FSBA. All additions were made on ice to prevent ATP hydrolysis and crosslinking of FSBA. The ATP hydrolysis was initiated by warming the reaction mixture to 37°C. Not only was the

inhibition of ATPase activity reversed, but there was a >4-fold stimulation of FSBA-mediated ATP hydrolysis; the concentration required for 50% stimulation was 0.07 ± 0.05 mM (Fig. 5A). Thus, it is plausible that FSBA also interacts with the substrate-binding sites of P-gp and as a consequence stimulates ATP hydrolysis. Moreover, when the NBDs are occupied by 5 mM ATP, FSBA affects the $V_{\max}$ but not the K_m of P-gp-mediated ATP hydrolysis (Fig. 5B), which suggests noncompetitive stimulation of the ATPase reaction ($V_{\max}$ 58.9/21.8, K_m 0.64/0.54 mM in the presence/absence of FSBA, respectively). This observation is consistent with the fact that the nucleotide- and substrate-binding sites are located on different domains of P-gp.⁹ To permit competition of FSBA and ATP at the NBDs, we incubated FSBA in the presence of ATP for 30 min at 37°C. This incubation was carried out in the absence of Mg^{2+} , permitting both ATP and FSBA to interact with the NBDs. However, ATP hydrolysis would not occur, as Mg^{2+} is necessary for P-gp-mediated ATP hydrolysis.⁴⁶ ATP hydrolysis was initiated by the addition of Mg^{2+} to the reaction mixture. The presence of FSBA results in a ~3-fold increase in the K_m (ATP) 1.31/0.44 mM in the presence/absence of FSBA, respectively) (Fig. 5C). This decrease in the affinity of ATP suggests competitive inhibition (i.e., both FSBA and ATP compete for the same or similar sites on P-gp). As it is not possible to prevent FSBA interaction at the drug-substrate site in these experiments, some of the observed kinetic changes may be influenced by its effect on substrate-binding site in TMDs.

Interaction of FSBA with the Nucleotide- and Substrate-Binding Sites of P-gp

Previous studies have demonstrated that the nucleotide analog 8-azido- $[\alpha\text{-}^{32}\text{P}]\text{ATP}$ photocrosslinks specifically to the NBDs of P-gp and can be displaced by unlabeled nucleotides.³⁸ We demonstrate in Supplemental Fig. S2 that FSBA inhibits the photocrosslinking of 8-azido- $[\alpha\text{-}^{32}\text{P}]\text{ATP}$ to P-gp in a concentration-dependent manner with an IC_{50} of 0.68 ± 0.23 mM (mean $\pm$ SD; $n=3$). Similarly the photoaffinity analog of prazosin, $[\text{I}^{125}]\text{IAAP}$, which is transported by P-gp, has been used extensively to study interactions at the substrate-binding sites.⁴⁷ Drug-substrates of P-gp inhibit the photocrosslinking of $[\text{I}^{125}]\text{IAAP}$, but nucleotides such as ATP and ADP have no effect.³⁴ Although FSBA is a nucleotide analog, it inhibits the photocrosslinking of P-gp with $[\text{I}^{125}]\text{IAAP}$ with an IC_{50} of 0.17 ± 0.03 mM (Fig. 6A). The addition of ATP had no effect on the inhibitory effect of FSBA ($\text{IC}_{50}=0.09 \pm 0.04$ mM; $n=3$). Furthermore, similar IC_{50} value (0.20 ± 0.08 mM) was obtained using the double mutant Y401/1044A, in which the tyrosine residues in A-loops of both NBDs are replaced with alanine, and ATP is incapable of binding to the mutant P-gp (Fig 6B).⁴⁸ These results suggest that FSBA inhibits photolabeling of P-gp with $[\text{I}^{125}]\text{IAAP}$ either by directly interacting with substrate-binding sites or by binding elsewhere regardless of its interaction with the NBDs. Moreover, these data indicate that there are two types of interactions between P-gp and FSBA. One is the chemical crosslinking of FSBA to residues within or nearby NBDs affecting ATP sites. The other is an interaction most likely in the TMD region affecting the drug-substrate binding.

When FSBA was incubated with P-gp for 30 min at 4°C and then washed off by centrifugation, there was no inhibition of ATP hydrolysis (Fig 3C: compare the first two bars). On the other hand, if FSBA was incubated with P-gp at 37°C prior to removal of free FSBA by centrifugation, there was a significant inhibition of P-gp-mediated ATP hydrolysis (Fig. 3C: compare the third and fourth bars). These results suggest that FSBA does indeed crosslink to P-gp, but only at 37°C and not at 4°C. On the other hand, P-gp incubated with FSBA at 37°C and washed by centrifugation had no effect on the crosslinking of IAAP (Fig. 6C), suggesting that FSBA fraction that inhibits photolabeling with IAAP is washable and thus it likely interacts with but does not crosslink to the substrate-binding site(s). Similar results were obtained when the mutant P-gp (Y401A/Y1044A), which lacks the capacity to bind nucleotides, was used in lieu of the wild-type protein (Fig. 6D). These data suggest that

it is unlikely that crosslinking of FSBA occurs at the drug-substrate-binding sites in the TMDs.

Identification of FSBA-Labeled Sites Using Mass Spectrometry

Purified P-gp in proteoliposomes was crosslinked with 2 mM FSBA by incubation at 37°C for 30 min either in the presence or absence of 5 mM ATP. These samples were then electrophoresed and the excised protein bands were subjected to in-gel digestion followed by mass spectrometry analysis, as described in Materials and Methods. Fig. 7 shows an example of the MALDI-TOF mass fingerprinting results. The two panels show a portion of the mass spectrum of the P-gp tryptic digest untreated and after treatment with FSBA. As an example, the peptide at $m/z=898.95$ is shifted to $m/z=1331.85$ following FSBA modification. Table 1 lists all the peptides identified with crosslinking to FSBA. Of the seven peptides identified, four were not crosslinked in the presence of ATP. It is noteworthy that no crosslinked peptides were identified in the TMDs, although peptides from the TMDs were observed in the untreated sample. These data demonstrate that FSBA crosslinks to residues within or nearby the NBDs of P-gp, while crosslinking to the TMDs is not detectable.

Molecular Modeling of FSBA Interaction at the NBDs of P-gp

As there is no available X-ray crystal structure of human P-gp, a NBD homology model of P-gp on the basis of the haemolysin transporter (Hly-B) was built as described in Materials and Methods. The Hly-B structure (1XEF.pdb) was selected as a template for the following three reasons: high similarity between sequences at the NBDs, the fact that the Hly-B protein was crystallized with bound ATP and Mg^{2+} and the acceptable resolution of the structure (2.5 Å). The molecular modeling studies were carried out with the aim of better understanding the biochemical data presented here: (i) FSBA and ATP compete for the same site at the NBDs of P-gp and (ii) chemical crosslinking of FSBA to residues within or nearby NBDs. The highly similar structures of FSBA and ATP suggest that FSBA binds at the ATP binding site in the same fashion as ATP, with the adenine group π -stacked to the A-loop tyrosine 401 of NBD1 or the Y1044 of NBD2.^{48, 49} This typical binding mode set the conditions for the modeling studies. The program Vina-autodock was used to predict the possible non-covalent binding of FSBA at the nucleotide-binding sites. In fact, FSBA fits effectively at the NBDs with the adenine group interacting with Y401 (NBD1) or Y1044 (NBD2) through π - π contact, and the fluorosulfonyl moiety at the approximate position typically occupied by the ATP β - and γ -phosphate (see Fig. 8A and 8B). However, this pocket is surrounded by positively charged residues such as Walker A lysine-433 and also a Mg^{2+} ion, which creates an environment that's better suited for negatively-charged ligands (ATP) than neutral ones (FSBA).

Further modeling was carried out to investigate other FSBA-protein interactions that better account for the efficient inhibition of ATP hydrolysis. The electrophilic fluorosulfonyl group of FSBA is reactive towards Lewis bases such as the side-chains of lysine, tyrosine, histidines, serine and cysteine,¹⁵ and responsible for the chemical crosslinking to the NBDs of P-gp. Therefore, modeling studies having both (i) the FSBA adenine moiety π -stacked to the Y401, and (ii) the fluorosulfonyl group pointed to any basic residue of the fragments identified as crosslinked to FSBA by LC/MS/MS (see Table 1) were performed. One FSBA molecule was successfully modeled with the fluorosulfonyl group pointing towards the amino group of Lys-411 (Fig. S3), thus offering an explanation for the origin of peptide fragment #2 detected by LC/MS/MS (see Figures 7, 8C, 8D and Table 1) and also providing an alternative mode that accounts for the efficient inhibition of ATP hydrolysis by FSBA. Interestingly, when FSBA is modeled at NBD2, the fluorosulfonyl group points to a glutamine residue (Q1054, the equivalent residue of K411 at NBD2), a much weaker Lewis

base than lysine, providing a plausible explanation as to why the equivalent fragment of NBD1 at NBD2 is not found crosslinked to FSBA. Although FSBA could not be docked to explain the origin of the rest of the peptide fragments detected by MS, it is important to mention that just a small movement of loops next to the ATP site would make possible docking with the adenine moiety π -stacked to the A-loop tyrosine and the reactive $-SO_2F$ group pointing to K1102 (fragment #4 in Table 1), to H398 (fragment #5) and R459 (fragment #6). Although arginine has not been reported frequently as a target for FSBA, it has also been found crosslinked to FSBA.⁵⁰ The location of FSBA peptides labeled 2 to 7 (Table 1) in the homology model of human P-gp NBDs is shown in Fig. 8C and D. Earlier reports indicated that FSBA could react with several different nucleophilic amino acids.^{17, 20} While lysine, tyrosine, and histidine residues are part of the sequence of the FSBA-crosslinked peptides, no cysteine is found in any of them. Our results with the Cys-less P-gp (see Fig. 4B) and FSBA-labeled P-gp peptides (Table 1) are also in agreement with these studies.

A homology model of human P-gp on the basis of the recently published X-ray structure of mouse P-gp was also built and subjected to docking analysis. The mouse P-gp sequence is very similar to human P-gp (87% identity) but the X-ray structure reported has two significant disadvantages: low resolution (3.8 Å) and the fact that it was obtained in the absence of nucleotide. Interestingly, we found that FSBA (as well as ATP) cannot be docked in the same way as in the model based on Hly-B structure because the conformation of the Walker A motif is different (Fig. S4). This suggests that a homology model of NBDs of human P-gp based on Hly-B structure (with bound ATP/Mg²⁺) is the appropriate one for docking studies of FSBA.

DISCUSSION

In this report, we have characterized in considerable detail the interactions of FSBA with P-gp. The main reason for this is that FSBA is an ATP analog and it has been used extensively to chemically modify and probe the nucleotide-binding sites of proteins that bind and hydrolyze nucleotides.¹⁴ This could thus also be a useful reagent to study the NBDs of P-gp as well as other ABC transporters.

The reports in the literature primarily consider FSBA as a nucleotide analog¹⁴ for kinases and other ATP-binding proteins. However, our results show that FSBA interacts with NBDs and also has an effect on the substrate-binding sites of P-gp (Fig. 2, 5A, and 6). In intact cells, FSBA, similar to other P-gp inhibitors (XR9576), blocked the efflux of rhodamine 123 (Fig. 2), suggesting that FSBA inhibits P-gp mediated transport in intact cells by interacting at the transport-substrate sites in the TMDs rather than in the NBDs, as one would expect that the NBD sites are occupied by ATP under physiological conditions with the intracellular concentration of ATP in the range of 3–5 mM. Most nucleotides (and nucleotide analogs) are not transport-substrates of P-gp and the transport-substrates do not directly interact with the NBDs.¹⁰ This is consistent with a large body of work that shows that ATP hydrolysis and drug-substrate transport occur at different domains.⁹ The TMDs are anchored in the plasma membrane and interact with the transport-substrates which are generally hydrophobic, while the NBDs, which are physically located in the cytoplasm, interact with hydrophilic nucleotides.⁹ In FSBA, the benzoylsulfonyl fluoride replaces the tri-phosphate moiety of ATP (Fig. 1B). As a result, unlike ATP, which is negatively charged, FSBA is neutral¹⁵ and there is the addition of an aromatic benzoyl group. These changes make FSBA more hydrophobic (Log P = 2.64), thus penetrating the membrane domains and providing it with structural features that characterize transport substrates of P-gp. This can explain how FSBA is able to interact with the drug-substrate-binding sites of P-gp. We provide evidence for the effect of FSBA on the substrate-binding sites in Fig. 6A,B.

The prazosin analog IAAP has been used extensively as a photoaffinity probe for the substrate-binding sites of P-gp.⁴⁷ The concentration-dependent inhibition of IAAP binding to P-gp by FSBA (Fig. 6A,B) demonstrates that FSBA interacts directly with the substrate-binding site(s). It has been pointed out previously that the replacement of the phosphate groups of ATP with the sulfonylfluoride group makes FSBA uncharged and a less desirable ATP analog;¹⁵ however, these modifications make FSBA more accessible to the substrate-binding site(s) (see above). In addition, there appear to be different energetic requirements for binding to the ATP sites and chemical crosslinking. The former can be demonstrated by the virtually instantaneous displacement of 8-azido- $[\alpha\text{-}^{32}\text{P}]\text{-ATP}$ by FSBA at 4°C. On the other hand, the irreversible FSBA-mediated inhibition of ATP hydrolysis (as a consequence of chemical crosslinking) has a $t_{1/2}$ of approximately 4 min (Fig. 3B), and this inhibition is strongly temperature-dependent (Fig. 3C). It is clear that while the reversible binding of FSBA to NBDs is temperature-independent, the chemical crosslinking to residues within and nearby NBDs is temperature-dependent.

The sulfonyl fluoride group of FSBA, which replaces the phosphate groups of ATP, is a reactive functional group that can react with several amino acids.^{16–18} It has been argued that as the sulfonyl fluoride participates in a broad range of reactions, there is a reasonable probability of reaction within any particular active site.¹⁵ To distinguish between covalent and non-covalent interactions, P-gp was incubated for 30 min in the absence or presence of FSBA. Reactions were carried out either at 4°C or 37°C and the excess unreacted FSBA was removed by dilution with cold buffer followed by centrifugation. The P-gp samples that were incubated with FSBA at 37°C showed a strong inhibition of ATP hydrolysis (Fig. 3C: compare third and fourth bars), while those incubated at 4°C showed no inhibition (Fig. 3C: compare first and second bars). The control (incubation at 4°C) shows that un-reacted FSBA can be effectively removed by centrifugation and it is only the chemically-crosslinked FSBA that inhibits ATP hydrolysis. The binding of the transport substrate IAAP to wild-type P-gp or mutant Y401A/1044A (that cannot bind to ATP) is not affected by the formation of an FSBA-P-gp adduct (Fig. 6C,D), suggesting that FSBA is not crosslinked to the IAAP binding site. Thus, the interaction of FSBA at the drug-substrate binding pocket in TMDs is reversible and it does not depend on the functional status of ATP sites (Fig. 6A,B).

The covalent crosslinking of FSBA to P-gp is further verified by crosslinking of $[\text{}^{14}\text{C}]\text{-FSBA}$ to purified P-gp reconstituted into proteoliposomes (Fig. 4A). In addition, we used mass spectrometry to identify sites on P-gp labeled with FSBA (Fig. 7). Seven peptides were labeled with FSBA, of which four were protected by pretreatment with 5 mM ATP (Table 1). This is consistent with the observation that incubation with a saturating concentration of ATP prior to addition of FSBA provides only partial protection to labeling by $[\text{}^{14}\text{C}]\text{-FSBA}$ (Fig. 4A). Identification of the peptides labeled with FSBA further suggests that FSBA crosslinks mainly to residues within or near the NBDs (five out of seven fragments are within or near the ATP sites; Table 1, and Figs. 7 and 8C, D), despite interrogating both the nucleotide- and substrate-binding sites (Figs. 3, 6).

Previous studies have shown that FSBA participates in covalent reactions with various amino acids (for review see ¹⁵), including tyrosine, lysine, histidine, serine, and cysteine. The X-ray crystal structures of the NBD domains of several ABC transporters (e.g. MJ0796-1L2T.pdb; Hly-B -1XEF.pdb) show that the ATP molecule is sandwiched between the A-loop, the Walker A & B domains and the H-loop of one NBD and the signature sequence and D-loop of the opposing NBD.^{39, 51} Docking studies of FSBA at both ATP sites show the sulfonyl fluoride moiety of FSBA (which is the reactive group) is located close to the position normally occupied by the β - and γ -phosphate of ATP (see Figs 8A,B). Therefore, residues such as the cysteine, serine and lysine of Walker A, the histidine of the H-loop and the serine of the signature motif are potential targets for FSBA. However, all

those residues (except the H loop-histidine) are not properly oriented for chemical reaction to the partially positively charged sulfur of FSBA. The H loop-histidine seems to be suitably oriented for reaction, but is too far (more than 5 Å) from the reactive fluorosulfonyl group. In addition, LC/MS/MS analysis of P-gp labeled with FSBA did not yield any fragment with residues responsible for binding ATP (Fig. 7 and Table 1). On the other hand, modeling studies yielded a reasonable explanation for the origin of fragment #2, and further structural analysis revealed that just small conformational changes at loops close to the ATP sites are necessary to explain the origin of fragments #4, #5, and #6. However, the fact that ATP does not prevent crosslinking of three fragments out of seven suggests that FSBA is also binding to P-gp at other sites near the NBDs (see comments column in Table 1).

Tyrosine kinase inhibitors, which are developed based on their ability to bind to the catalytic site and prevent ATP binding (gleevec, nilotinib, etc.), interact at the drug-substrate sites of P-gp and ABCG2 but not at the ATP sites.⁵² FSBA is, to our knowledge, the first ATP analog that has an effect on the both the drug-substrate and ATP sites of P-gp, providing a unique and useful tool for biochemical studies of other ABC drug transporters including ABCG2, ABCC1, ABCC2, ABCC4 and ABCC7.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Mr. George Leiman for editorial assistance.

Abbreviations

ABC	ATP binding cassette
ABPP	Activity-based protein profiling
FSBA	5'-fluorosulfonylbenzoyl 5'-adenosine
IAAP	Iodoarylazidoprazosin
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
MDR	Multidrug resistance
NBD	Nucleotide binding domain
P-gp	P-glycoprotein
TMD	Transmembrane domain
Vi	Sodium orthovanadate

References

1. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. *Annu Rev Genomics Hum Genet.* 2005; 6:123–142. [PubMed: 16124856]
2. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. *J Bioenerg Biomembr.* 2001; 33:453–458. [PubMed: 11804186]
3. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta.* 1976; 455:152–162. [PubMed: 990323]
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer.* 2002; 2:48–58. [PubMed: 11902585]

5. Davidson AL. Mechanism of coupling of transport to hydrolysis in bacterial ATP-binding cassette transporters. *J Bacteriol.* 2002; 184:1225–1233. [PubMed: 11844750]
6. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem.* 1993; 62:385–427. [PubMed: 8102521]
7. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. *Nat Struct Mol Biol.* 2004; 11:918–926. [PubMed: 15452563]
8. Senior AE, al-Shawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. *FEBS Lett.* 1995; 377:285–289. [PubMed: 8549739]
9. Ambudkar SV, Kim IW, Sauna ZE. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). *Eur J Pharm Sci.* 2006; 27:392–400. [PubMed: 16352426]
10. Sauna ZE, Ambudkar SV. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. *Mol Cancer Ther.* 2007; 6:13–23. [PubMed: 17237262]
11. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. *Methods Enzymol.* 1998; 292:504–514. [PubMed: 9711578]
12. al-Shawi MK, Urbatsch IL, Senior AE. Covalent inhibitors of P-glycoprotein ATPase activity. *J Biol Chem.* 1994; 269:8986–8992. [PubMed: 7907596]
13. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. *Oncogene.* 2003; 22:7468–7485. [PubMed: 14576852]
14. Cravatt BF, Wright AT, Kozarich JW. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. *Annu Rev Biochem.* 2008; 77:383–414. [PubMed: 18366325]
15. Colman RF. Affinity labeling of purine nucleotide sites in proteins. *Annu Rev Biochem.* 1983; 52:67–91. [PubMed: 6311082]
16. Fox T, Fitzgibbon MJ, Fleming MA, Hsiao HM, Brummel CL, Su MS. Kinetic mechanism and ATP-binding site reactivity of p38gamma MAP kinase. *FEBS Lett.* 1999; 461:323–328. [PubMed: 10567720]
17. Renzone G, Salzano AM, Arena S, D'Ambrosio C, Scaloni A. Selective ion tracing and MSn analysis of peptide digests from FSBA-treated kinases for the analysis of protein ATP-binding sites. *J Proteome Res.* 2006; 5:2019–2024. [PubMed: 16889425]
18. Zhou G, Charbonneau H, Colman RF, Zalkin H. Identification of sites for feedback regulation of glutamine 5-phosphoribosylpyrophosphate amidotransferase by nucleotides and relationship to residues important for catalysis. *J Biol Chem.* 1993; 268:10471–10481. [PubMed: 7683680]
19. Hagiwara M, Inagaki M, Hidaka H. Specific binding of a novel compound, N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) to the active site of cAMP-dependent protein kinase. *Mol Pharmacol.* 1987; 31:523–528. [PubMed: 3574296]
20. Oudot C, Jault JM, Jaquinod M, Negre D, Prost JF, Cozzone AJ, Cortay JC. Inactivation of isocitrate dehydrogenase kinase/phosphatase by 5'-[p-(fluorosulfonyl)benzoyl]adenosine is not due to the labeling of the invariant lysine residue found in the protein kinase family. *Eur J Biochem.* 1998; 258:579–585. [PubMed: 9874226]
21. Annamalai AE, Colman RF. Reaction of the adenine nucleotide analogue 5'-p-fluorosulfonylbenzoyl adenosine at distinct tyrosine and cysteine residues of rabbit muscle pyruvate kinase. *J Biol Chem.* 1981; 256:10276–10283. [PubMed: 7287711]
22. Kim HS, Lee L, Evans DR. Identification of the ATP binding sites of the carbamyl phosphate synthetase domain of the Syrian hamster multifunctional protein CAD by affinity labeling with 5'-[p-(fluorosulfonyl)benzoyl]adenosine. *Biochemistry.* 1991; 30:10322–10329. [PubMed: 1681900]
23. Bullough DA, Allison WS. Three copies of the beta subunit must be modified to achieve complete inactivation of the bovine mitochondrial F1-ATPase by 5'-p-fluorosulfonylbenzoyladenosine. *J Biol Chem.* 1986; 261:5722–5730. [PubMed: 2871017]
24. Khandekar SS, Feng B, Yi T, Chen S, Laping N, Bramson N. A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors. *J Biomol Screen.* 2005; 10:447–455. [PubMed: 16093554]
25. Hanouille X, Van Damme J, Staes A, Martens L, Goethals M, Vandekerckhove J, Gevaert K. A new functional, chemical proteomics technology to identify purine nucleotide binding sites in complex proteomes. *J Proteome Res.* 2006; 5:3438–3445. [PubMed: 17137346]

26. Aksamit RR, Backlund PS Jr, Moos M Jr, Caryk T, Gomi T, Ogawa H, Fujioka M, Cantoni GL. The role of cysteine 78 in fluorosulfonylbenzoyl adenosine inactivation of rat liver S-adenosylhomocysteine hydrolase. *J Biol Chem.* 1994; 269:4084–4091. [PubMed: 8307967]
27. Flores-Herrera O, Uribe A, Garcia-Perez C, Milan R, Martinez F. 5'-p-Fluorosulfonylbenzoyl adenosine inhibits progesterone synthesis in human placental mitochondria. *Biochim Biophys Acta.* 2002; 1585:11–18. [PubMed: 12457710]
28. Ratcliffe SJ, Yi T, Khandekar SS. Synthesis and characterization of 5'-p-fluorosulfonylbenzoyl-2' (or 3')-(biotinyl)adenosine as an activity-based probe for protein kinases. *J Biomol Screen.* 2007; 12:126–132. [PubMed: 17166825]
29. Luo JH, Aurelian L. The transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). *J Biol Chem.* 1992; 267:9645–9653. [PubMed: 1315764]
30. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. *J Natl Cancer Inst.* 2000; 92:898–902. [PubMed: 10841824]
31. Sauna ZE, Peng X-H, Nandigama K, Tekle S, Ambudkar SV. The Molecular Basis of the Action of Disulfiram as a Modulator of the Multidrug Resistance-Linked ATP Binding Cassette Transporters MDR1 (ABCB1) and MRP1 (ABCC1). *Mol Pharmacol.* 2004; 65:675–684. [PubMed: 14978246]
32. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM. Human multidrug-resistant cell lines: increased *mdr1* expression can precede gene amplification. *Science.* 1986; 232:643–645. [PubMed: 3457471]
33. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, Pastan I. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. *Biochemistry.* 1998; 37:5010–5019. [PubMed: 9538020]
34. Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. *Proc Natl Acad Sci U S A.* 2000; 97:2515–2520. [PubMed: 10716986]
35. Kerr KM, Sauna ZE, Ambudkar SV. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. *J Biol Chem.* 2001; 276:8657–8664. [PubMed: 11121420]
36. Schaffner W, Weissmann C. A rapid, sensitive, and specific method for the determination of protein in dilute solution. *Anal Biochem.* 1973; 56:502–514. [PubMed: 4128882]
37. Sauna ZE, Smith MM, Muller M, Ambudkar SV. Functionally similar vanadate-induced 8-azidoadenosine 5'-alpha-P-32 diphosphate-trapped transition state intermediates of human P-glycoprotein are generated in the absence and presence of ATP hydrolysis. *J Biol Chem.* 2001; 276:21199–21208. [PubMed: 11287418]
38. Sauna ZE, Kim IW, Nandigama K, Kopp S, Chiba P, Ambudkar SV. Catalytic cycle of ATP hydrolysis by P-glycoprotein: Evidence for formation of the E-S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. *Biochemistry.* 2007; 46:13787–13799. [PubMed: 17988154]
39. Zaitseva J, Jenewein S, Jumpertz T, Holland IB, Schmitt L. H662 is the linchpin of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter HlyB. *Embo J.* 2005; 24:1901–1910. [PubMed: 15889153]
40. Procko E, Ferrin-O'Connell I, Ng SL, Gaudet R. Distinct structural and functional properties of the ATPase sites in an asymmetric ABC transporter. *Mol Cell.* 2006; 24:51–62. [PubMed: 17018292]
41. Brooks BR, Brooks CL 3rd, Mackerell AD Jr, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoseck M, Im W, Kucsera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM, Karplus M. CHARMM: the biomolecular simulation program. *J Comput Chem.* 2009; 30:1545–1614. [PubMed: 19444816]

42. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem.* 2009; 31:455–461. [PubMed: 19499576]
43. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2. *Drug Metab Disposition.* 2009; 37:359–365.
44. Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. *Curr Drug Deliv.* 2007; 4:324–333. [PubMed: 17979652]
45. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. *Bioorg Med Chem Lett.* 1999; 9:595–600. [PubMed: 10098671]
46. Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. *Cancer Res.* 1988; 48:4926–4932. [PubMed: 2900677]
47. Peer M, Csaszar E, Vorlaufer E, Kopp S, Chiba P. Photoaffinity labeling of P-glycoprotein. *Mini Rev Med Chem.* 2005; 5:165–172. [PubMed: 15720286]
48. Kim IW, Peng XH, Sauna ZE, FitzGerald PC, Xia D, Muller M, Nandigama K, Ambudkar SV. The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: Evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. *Biochemistry.* 2006; 45:7605–7616. [PubMed: 16768456]
49. Ambudkar SV, Kim IW, Xia D, Sauna ZE. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. *FEBS Lett.* 2006; 580:1049–1055. [PubMed: 16412422]
50. Pandey VN, Modak MJ. Affinity labeling of Escherichia coli DNA polymerase I by 5'-fluorosulfonylbenzoyladenine. Identification of the domain essential for polymerization and Arg-682 as the site of reactivity. *J Biol Chem.* 1988; 263:6068–6073. [PubMed: 3283117]
51. Smith PC, Karpowich N, Millen L, Moody JE, Rosen J, Thomas PJ, Hunt JF. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. *Mol Cell.* 2002; 10:139–149. [PubMed: 12150914]
52. Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. *Leukemia.* 2008; 22:445–447. [PubMed: 17690695]

Figure 1. Chemical structures of ATP and FSBA. Comparison of the chemical structures of (A) ATP and (B) FSBA.

Figure 2.

Effect of FSBA on the P-gp-mediated transport of fluorescent substrate. A flow cytometry-based assay showed accumulation of the fluorescent P-gp transport substrate rhodamine 123. Parental, KB-3-1 (A) and P-gp-expressing KB-V1 (B) cells (300,000/tube) were incubated with 0.5 μ g/ml of rhodamine 123 for 45 min at 37°C in the dark, in the absence (control cells:—), or presence of 10 μ M XR 9576 (----) or 1.5 mM FSBA (.....). The cells were then washed, resuspended in PBS with 0.1% BSA, and analyzed by flow cytometer as described in Materials and Methods. Representative histograms generated with Cell Quest software from three independent experiments are depicted.

Figure 3.

Effect of FSBA on P-gp-mediated ATP hydrolysis. (A) Inhibition of P-gp ATPase activity by FSBA. Vanadate-sensitive P-gp-mediated ATP hydrolysis was measured as described in Materials and Methods in the presence of increasing concentrations of FSBA (0–2 mM). In this experiment the FSBA was incubated with P-gp (10 μ g protein/100 μ l) for 30 min at 37°C prior to addition of 5 mM ATP. The IC_{50} (FSBA) for inhibition of P-gp-mediated ATP hydrolysis is 0.21 ± 0.05 mM. A representative plot is shown ($n = 3$). (B) Time course of the inhibition by FSBA of P-gp-mediated ATP hydrolysis. ATP hydrolysis was measured for 20 min following incubation of P-gp (10 μ g/100 μ l) with FSBA (1 mM) for increasing amounts of time. The $t_{1/2}$ for the inhibition of ATP hydrolysis was 3.8 min. (C) Effect of temperature on the inhibition of P-gp-mediated ATP hydrolysis by FSBA. P-gp (10 μ g/100 μ l) was incubated for 30 min in the absence or presence FSBA (1 mM) at either 4°C or 37°C prior to initiating ATP hydrolysis at 37°C. The reaction conditions are shown on the figure. Data represent the mean values ($\pm$ SD) obtained from at least 3 independent experiments.

Figure 4.

Crosslinking of [^{14}C]FSBA to P-gp. (A) Purified P-gp (10–36 μg protein) reconstituted into proteoliposomes was incubated for 30 min at 37°C with 0.4 mM [^{14}C]FSBA in the presence or absence of 10 mM ATP. The samples were then electrophoresed and the dried gel was exposed to an X-ray film at -70°C for 3–7 days. (B) Purified wild-type P-gp and the cys-less mutant (60 μg protein) was reconstituted into proteoliposomes and incubated for 30 min at 37°C with 0.35 mM [^{14}C]FSBA. The samples were then electrophoresed, the dried gel was exposed to an X-ray film at -70°C for 3–7 days. In both (A) and (B) the section of the autoradiogram with the P-gp band is indicated and the bar graphs show the mean $\pm$ SD values following quantification, which was carried out using the STORM 860 PhosphorImager system with a high sensitivity screen and the software ImageQuaNT.

Figure 5.

Characterization of the FSBA-mediated stimulation of ATP hydrolysis by P-gp. (A) The experiment was performed as described in (Fig. 3A), except that a saturating concentration of ATP (5 mM) was added prior to the addition of FSBA. All additions were made on ice and the ATPase reaction was initiated by warming the tubes to 37°C. The concentration of FSBA required for 50% stimulation of P-gp-mediated ATPase activity of P-gp is 0.07 ± 0.05 mM. (B) Michaelis-Menten kinetics of P-gp-mediated ATP hydrolysis were determined in the absence (●) or presence (■) of FSBA (2 mM). K_m (ATP) values in the absence and presence of FSBA were 0.54 ± 0.17 mM and 0.64 ± 0.14 mM respectively and the V_{max} values were 21.4 and 58.9 nmol P_i /mg protein/min, respectively. Note that both ATP and FSBA were added at the same time without any prior incubation at 37°C. (C) Michaelis-Menten kinetics of P-gp-mediated ATP hydrolysis were determined in the absence (●) or presence (■) of FSBA (2 mM). P-gp was incubated in the presence or absence of FSBA (2 mM) and 5 mM ATP for 30 min at 37°C in the absence of Mg^{2+} . ATP hydrolysis was then initiated by the addition of 10 mM $MgCl_2$. K_m (ATP) values, in the absence and presence of FSBA, were 0.44 ± 0.14 mM and 1.31 ± 0.18 mM, respectively. The data points in all graphs (A,B,C) represent the mean values $\pm$ SD obtained from at least three independent experiments and the kinetic parameters were estimated using the curve-fitting software GraphPad PRIZM.

Figure 6.

FSBA binds to the drug-substrate site(s) and inhibits photolabeling of P-gp with $[^{125}\text{I}]\text{IAAP}$. (A) The apparent affinities of FSBA for the substrate-binding sites of WT-P-gp were estimated by monitoring the crosslinking of the photoaffinity analog of prazosin, $[^{125}\text{I}]\text{IAAP}$ in the presence of increasing concentrations of FSBA (0–2 mM) in the absence (●) or presence of 5 mM ATP (■), as described in Materials and Methods. (B) The apparent affinity of FSBA for the substrate-binding sites of the Y401A/Y1044A mutant-P-gp, which cannot bind ATP, was estimated as described in (A). For experiments in (A) and (B), 5–7 nM $[^{125}\text{I}]\text{IAAP}$ was used. Photoaffinity labeling of wild-type (C) and Y401A/1044A mutant (D) with IAAP after the formation of FSBA-P-gp adduct. P-gp containing crude membranes (500 μg protein) was treated with or without FSBA (2 mM) in 1 ml ATPase buffer for 30 min at 37°C. The samples were washed by centrifugation at $200,000 \times g$ for 20 min at 4°C to remove the excess FSBA, resuspended in ice-cold 150 μl of ATPase buffer, and 10 μl washed membranes (50–75 μg protein) were incubated with 10 nM IAAP and photocrosslinked as described in Materials and Methods. Finally, all samples were electrophoresed and the dried gel was exposed to an X-ray film. The upper panel depicts the autoradiogram from a representative experiment and similar results were obtained in two additional experiments. The radioactivity associated with the P-gp band was quantified and represented in the lower panels using a phosphorimager and the curve-fitting software

GraphPad PRIZM (for panels A and B). In (A) upper, an autoradiogram depicts FSBA treatment in the absence (free) and the presence of 5 mM ATP (protected).

Figure 7.

Identification of FSBA-labeled sites using MALDI-TOF MS. Purified and reconstituted P-gp (10–20 μ g protein) was incubated with 2 mM FSBA at 37°C for 30 min either in the presence or absence of 5 mM ATP. The samples were run on a 7% NuPage gel at constant voltage (150 V). Protein (P-gp) bands excised from polyacrylamide gels were subjected to in-gel trypsin digestion followed by MALDI-TOF MS, as described in the Materials and Methods. Representative regions of the MS spectrum of control, i.e. untreated (bottom), or FSBA-treated (top) are shown. The peak at $m/z=898.95$ represents an unmodified peptide (peptide# 2 in Table 1) that shifts to $m/z=1331.85$ following FSBA modification (marked with an arrow).

Figure 8.

Modeling of FSBA in NBDs of human P-gp. The homology model of NBDs of human P-gp using the HlyB NBD structure was generated as described in Materials and Methods. (A) Modeling of FSBA at the NBD1. The FSBA molecule is docked at the NBD1 with its adenine group π -stacked to the aromatic ring of Y-401 (A-loop). An original FSBA conformation was generated by the program Vina-Autodock, and then the protein-FSBA complex was energy-minimized using CHARMM. (B) Modeling of FSBA at the NBD2. The FSBA molecule is docked at nucleotide-binding site 2 with its adenine group π -stacked to the aromatic ring of Y-1044 (A-loop). An original FSBA conformation was built manually into the NBD2 through molecular torsions, and then the protein-FSBA complex was energy-minimized using CHARMM. (C) and (D) Location of the FSBA-labeled peptides in the model of human P-gp NBDs. The peptides are painted in different colors and numbered the same as in Table 1. Target residues are also shown in stick models and labeled. The NBD model is shown in two orientations: (C) NBD1 to the left and NBD2 to the right and (D) NBD2 to the left and NBD1 to the right. Figures in A and B are colored as: NBD1=cyan, NBD2=magenta; ATP=blue and FSBA=red; Y-401/Y-1044=orange. Figure C and D: NBD1=light grey, NBD2=dark grey; O=red, N=blue, S=yellow, F=light blue, P=orange, Mg^{2+} =black ball (only shown in C and D); and created with PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC).

Table 1

FSBA-crosslinked peptides in P-gp

Peptide	m/z	P-gp residue numbers	Sequence	NBD	ATP prevents crosslinking ^d	Target residue	Comments
1	715.99	790–794	YMFVR	_b	No		Distal to NBD1
2	898.95	409–416	ILKGLNLK	1	No	Lys-411	Within the NBD1 region
3	944.92	610–617	GNHDELMK	1	Yes		Distal to the H-loop in NBD1
4	1015.73	1094–1102	VLLDGKEIK	2	Yes	Lys-1102	Within the NBD2
5	1107.45	396–404	NVHFSYPSR	1	No	His-398 ^d	Very close to the A-loop (Y401) in NBD1
6	1910.55	443–459	LYDPTEGMVSVDGQDIR	1	Yes	Arg-459 ^d	Within the NBD1
7	2249.76	625–645	LVTMQTAGNEVELENAADESK	_c	Yes		Distal to NBD1 in the linker region

The FSBA labeled purified P-gp bands excised from NuPage gels were subjected to in-gel trypsin digestion followed by MALDI-TOF MS (see legend to Fig. 7 for experimental conditions).

^a Purified P-gp incubated with 5 mM ATP before addition of FSBA. “No” indicates crosslinking with FSBA is not prevented by pretreatment with ATP whereas “Yes” indicates inhibition by ATP;

^b Intracellular loop 3 (ICL3);

^c Linker region, most of the peptide outside the NBD1 region; and

^d Potential target residues.